Skip to main content
. 2019 May 28;116(24):11978–11987. doi: 10.1073/pnas.1819992116

Fig. 6.

Fig. 6.

(A) CD34+CD33Del cells resist CD33-targeted immunotherapy and contribute to myelopoiesis and lymphopoiesis. Left two panels in each condition is monitoring overtime of the repopulation of myeloid progenitors, and Right two panels shows lymphoid progenitors and mature cells in BM aspirates. No significant differences were observed between different treatment groups at all time points analyzed. (BD) CD34+CD33WT cells are sensitive to CD33-targeted immunotherapy. (B) A schematic of experimental design: 5 × 105 CD34+CD33WT alone or in combination with 5 × 105 HL-60 were injected in NSGS mice on day 0. One week after, mice were treated with PBS or allogeneic CART33 cells. Leukemia progression and CD34+CD33WT engraftment were then monitored by bone marrow aspiration at week 3 for CART33. The same day a group of mice was injected with GO and analyzed 4 d after. (C and D) BM aspirates show complete elimination of CD33WT leukemia cells (C) and CD33WT primary cells (D) in mice treated with CART33 or GO compared with PBS alone. Significant difference was observed between CART33 and GO compared with PBS. CD34+ injected derived human cells were gated on Ter119dtomato, Ly5/H2kd human CD45+CART. All data are represented as mean ± SEM (two independent experiments, two donors). Mouse and syringe images designed by Freepik and Kiranshastry from Flaticon.